(Bloomberg) — Biogen Inc.’s experimental Alzheimer’s disease therapy failed to gain support from a panel of U.S. Food and Drug Administration advisers on Friday, putting the drug at a crossroads as the agency weighs approval.The advisers voted 8 to 1, with 2 undecided, that data from a single clinical trial with positive results was insufficient to show the drug works in light of conflicting evidence from a different trial. The vote contradicts a report FDA reviewers prepared ahead of the meeting that supported the efficacy of the drug, called aducanumab, though there was dissent in the agency.Shares of Biogen were …read more
Source:: Yahoo Finance
